ACTU PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

ACTU ▲ +43.03% at T+20d

LONG call ✓ call won +43.03% · α vs SPY +36.73% · entry $2.08 → $2.98

Next anchor: T+60d in 7w

Last close $2.38 (close May 22) · +14.42% from $2.08 entry

Entry anchored
Apr 13, 03:59 PM ET
via Databento tick

T+1d

+3.37%

call +3.37% · α +2.59%

$2.15

settled 6w ago

T+5d

+8.89%

call +8.89% · α +7.50%

$2.27

settled 5w ago

T+20d

+43.03%

call +43.03% · α +36.73%

$2.98

settled 12d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Actuate Therapeutics announced positive Phase 2 trial results for elraglusib in metastatic pancreatic cancer, showing a 2.9-month improvement in median overall survival (10.1 vs 7.2 months) and a 38% reduction in risk of death. The data, published in Nature Medicine, demonstrate clinically meaningful survival benefits and immunomodulatory effects, supporting further development of elraglusib as a first-line combination therapy.

Actionable Insight

The magnitude of survival benefit and biomarker support makes this a strong catalyst for partnership interest or accelerated development. Traders should monitor for upcoming FDA interactions, trial expansion plans, or financing needs given the company's limited cash runway into July 2026.

Key Facts

Phase 2 trial showed median overall survival of 10.1 months with elraglusib + GnP vs 7.2 months with GnP alone
38% reduction in risk of death (HR 0.62; p=0.01)
1-year survival rate doubled to 44.1% vs 22.3% in control arm
Results published in peer-reviewed journal Nature Medicine
Company has not yet initiated pivotal trials or filed for approval; drug remains investigational

Financial Impact

High potential long-term value given unmet need in pancreatic cancer, though near-term dilution risk exists due to going-concern uncertainty

market sentimentdevelopment pipeline valueinvestor confidence

Risk Factors

Requires additional capital beyond July 2026; going concern uncertainty remains
Phase 3 trial not yet initiated; regulatory approval not guaranteed
Toxicity profile includes higher rates of Grade ≥3 neutropenia and fatigue

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3273413

5 reports for ACTU

T+1T+5T+20T+60

Filters

Reports for ACTU — sortable, filterable
	Type				Now
May 11, 2026 12d ago	8-K MIXED ★ 7/10	$2.89 $2.43	▼ −15.92%	▼ −15.99%	$2.38 (−17.65%)
May 6, 2026 17d ago	DEFA14A NEUTRAL ★ 4/10	$2.99 $2.89	▼ −3.34%	▼ −4.48%	$2.38 (−20.40%)
May 6, 2026 17d ago	8-K NEUTRAL ★ 4/10	$2.99 $2.89	▼ −3.34%	▼ −4.48%	$2.38 (−20.40%)
Apr 14, 2026 5w ago	Press Release BULLISH ★ 8/10	$2.08 $2.27	▲ +8.89%	▲ +7.50%	$2.38 (+14.42%)
Mar 9, 2026 10w ago	Press Release NEUTRAL ★ 4/10	$2.95 $2.68	▼ −9.00%	▼ −7.64%	$2.38 (−19.19%)

US Market Status

Market Closed — Opens Tue (34h 51m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access